The effect of alisertib and brigatinib on the activity of selected human carbonyl reducing enzymes. by Lakomá, Petra
ABSTRACT 
 
Charles University  
Faculty of Pharmacy in Hradec Králové  
Department of Biochemical Sciences 
 
Candidate: Petra Lakomá  
Supervisor: RNDr. Eva Novotná, Ph.D. 
Title of diploma thesis: The effect of alisertib and brigatinib on the activity of selected human 
carbonyl reducing enzymes  
Key words: brigatinib, alisertib, daunorubicin, inhibition, carbonyl-reducing enzymes 
 
Protein kinases are enzymes, whose main function is based on a transfer of phosphate 
group from ATP to protein substrate. This common posttranslational modification is involved 
in the regulation of intracellular processes and cell signaling. Altered expression of protein 
kinases is often coupled with a development of cancer. Inhibition of protein kinases may 
prevent cancer cell proliferation and induce their cell death. 
The main aim of the diploma thesis was to measure inhibition potential of protein kinase 
inhibitors, alisertib and brigatinib, against carbonyl-reducing enzymes. Overexpression 
of carbonyl-reducing enzymes in cancer cells may cause resistance to drugs followed by failure 
of chemotherapeutic therapy. In case of antracyclin chemotherapeutic daunorubicin, 
carbonyl-reducing enzymes reduce the carbonyl in C-13 giving rise a primary metabolite 
daunorubicinol, which has lower cytotoxic effect but higher cardiotoxicity. The effort 
to overcome resistance to daunorubicin and to decrease its cardiotoxic effects leads to search 
for inhibitors of carbonyl-reducing enzymes.  
Based on a comparison of specific activity of carbonyl-reducing enzymes, 
which metabolize danorubicin to daunorubicinol, we found, that the highest activity was 
reached in enzyme CRB1, whereas specific activity of other enzymes decreased in following 
order AKR1C3, AKR1A1, AKR1B10, AKR7A2 and AKR1B1. Those active enzymes were 
treated with potential inhibitors – alisertinib and brigatinib. Alisertib in 50 µM concentration 
reduced activity of enzyme AKR1C3 to 14.24 % and AKR1B10 to 44.30 %. In case of alisertib, 
we determined the IC50 and Ki value for AKR1C3. 
